Reber Genetics Co.
Developer and manufacturer of animal vaccines focused on gene-engineered subunit and inactivated vaccines. The company applies reverse genetic engineering and targeted fusion-antigen design, combined with AI-enabled antigen screening, to accelerate vaccine discovery for swine diseases. Operates a PIC/S-GMP–compliant vaccine production facility and provides contract R&D, manufacturing (CDMO), clinical trial (CRO) and veterinary support services for animal health markets.
Industries
Nr. of Employees
medium (51-250)
Reber Genetics Co.
Patents
Vaccine composition and method of preventing porcine epidemic diarrhea virus infection in swine
US-11413347-B2
View DetailsVaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases
US-10010602-B2
View Details
Vaccine composition and method of preventing porcine epidemic diarrhea virus infection in swine
US-11413347-B2
View DetailsVaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases
US-10010602-B2
View DetailsProducts
Subunit vaccine for porcine reproductive and respiratory syndrome (PRRS)
A gene-engineered subunit vaccine targeting PRRS to induce cellular and humoral responses in swine (described as a first-in-region subunit PRRS vaccine by the company).
Subunit vaccine for porcine circovirus type 2 (PCV2)
A subunit vaccine developed for PCV2 to control porcine circovirus-associated disease in swine.
Dual-antigen subunit/inactivated vaccine for porcine epidemic diarrhea (PED)
A combined vaccine formulation containing inactivated whole-virus particles and a spike-protein–derived subunit antigen designed to protect against PED outbreaks.
Subunit vaccine for porcine reproductive and respiratory syndrome (PRRS)
A gene-engineered subunit vaccine targeting PRRS to induce cellular and humoral responses in swine (described as a first-in-region subunit PRRS vaccine by the company).
Subunit vaccine for porcine circovirus type 2 (PCV2)
A subunit vaccine developed for PCV2 to control porcine circovirus-associated disease in swine.
Dual-antigen subunit/inactivated vaccine for porcine epidemic diarrhea (PED)
A combined vaccine formulation containing inactivated whole-virus particles and a spike-protein–derived subunit antigen designed to protect against PED outbreaks.
Services
Design and execution support for animal clinical trials, case management, data collection, toxicology assessments and research support.
Product development from concept to small-scale production, process optimization, technology transfer and commercial manufacturing under PIC/S GMP.
Customized vaccination schedules, on-site administration, animal health monitoring and emergency outbreak response.
Regular serological surveillance, RT-PCR and ELISA testing for pathogen detection and epidemiological monitoring.
Project coordination, budget and timeline management, and structured data integrity systems for R&D and regulatory submissions.
Design and execution support for animal clinical trials, case management, data collection, toxicology assessments and research support.
Product development from concept to small-scale production, process optimization, technology transfer and commercial manufacturing under PIC/S GMP.
Customized vaccination schedules, on-site administration, animal health monitoring and emergency outbreak response.
Regular serological surveillance, RT-PCR and ELISA testing for pathogen detection and epidemiological monitoring.
Project coordination, budget and timeline management, and structured data integrity systems for R&D and regulatory submissions.
Expertise Areas
- Vaccine research and development (animal vaccines)
- Subunit and inactivated vaccine platform development
- GMP-compliant vaccine manufacturing and scale-up
- Clinical trial and field study management for veterinary products
Key Technologies
- Subunit vaccine development
- Reverse genetic engineering
- Fusion-antigen design
- AI-driven antigen screening
News & Updates
Company visited and exchanged technology with a Japanese partner to explore insect-cell protein expression techniques for potential vaccine/antigen production applications.
Participation at the 2025 Asia Pig Veterinary Society meeting to present vaccine technologies and engage in international collaboration.
Case sharing of emergency use of a dual-antigen PED vaccine combining inactivated virus and a subunit spike-protein antigen during PED-positive outbreaks.
Facility successfully inspected and certified against PIC/S GMP standards, enabling GMP-compliant production for animal vaccines.
Reported receipt of national quality marks and approvals for vaccine products and multiple international product registrations (examples include Thailand, Korea, Philippines, Vietnam, Russia).
Company visited and exchanged technology with a Japanese partner to explore insect-cell protein expression techniques for potential vaccine/antigen production applications.
Participation at the 2025 Asia Pig Veterinary Society meeting to present vaccine technologies and engage in international collaboration.
Case sharing of emergency use of a dual-antigen PED vaccine combining inactivated virus and a subunit spike-protein antigen during PED-positive outbreaks.
Facility successfully inspected and certified against PIC/S GMP standards, enabling GMP-compliant production for animal vaccines.
Reported receipt of national quality marks and approvals for vaccine products and multiple international product registrations (examples include Thailand, Korea, Philippines, Vietnam, Russia).